With programmable RNAi medicines drug developers have the extraordinary ability to target the genetic root cause of disease. However the inability to deliver these therapeutic RNA molecules to cell types beyond the liver is holding back the progress of RNA medicine. Of the 500 or so cell types in our body, today only one cell (liver hepatocyte) has a clinically approved delivery system for RNAi.
To address the delivery problem, we investigated how RNA is naturally delivered to different cell and tissue types. What we realized is that nature has evolved an ecosystem of RNA delivery mechanisms to facilitate cell-cell communication. While conventional thought had assumed this RNA must be packaged in lipidic capsules, such as exosomes or vesicles, over 99% of RNA is not encapsulated.
Inspired by the ecosystem of RNA, we designed Mergo® – a programmable RNA tag – to encode RNA modifications and other iterable design elements to influence the delivery destination. It is a radically new approach to RNA delivery that works with biology, rather than forced cellular entry.
You can read more about our ‘revolution’ in targeted delivery in Nature Biopharma:
Mergo® is powered by a revolutionary system that combines evolution's ability to solve highly complex problems with the speed of computation. Made with automation, tested at scale and optimized with AI.
Entire Mergos are generated using machine learning and encoded into a chemical space. We have a manufacturable library of >100,000 machine learning-generated Mergos to select from, giving us an unparalleled and diverse space to optimize in.
Innovative chemistry for rapid production combined with lab automation and intelligent Design of Experiments (DoE) enable high-throughput Mergo generation.
We can test multiple Mergos in one biological model with cellular resolution, allowing us to solve multiple complex questions in parallel, dramatically reducing the time and cost of data acquisition.